摘要
目的研究国产重组人血管内皮抑素在体外对人乳腺癌MCF-7细胞增殖抑制、细胞周期及HIF-1α蛋白表达的影响。方法应用MTT法检测重组人血管内皮抑素对人乳腺癌MCF-7细胞的生长抑制率、FCM法分析细胞周期变化状况、ELISA法检测处理前后细胞中HIF-1α蛋白表达量。结果重组人血管内皮抑素作用于MCF-7细胞24、48及72 h后的细胞生长抑制率分别为6.9%、10.3%、43.1%。重组人血管内皮抑素可引起MCF-7细胞G2/M期阻滞,随着作用时间的延长阻滞明显。重组人血管内皮抑素可抑制HIF-1α蛋白表达,随着作用时间的延长表达水平下降。结论重组人血管内皮抑素能抑制MCF-7细胞的增殖,其抑制作用可能与G2/M期阻滞有关。重组人血管内皮抑素可以抑制肿瘤细胞HIF-1α蛋白表达,其过表达是肿瘤细胞抵抗放化疗的因素之一,因此联合重组人血管内皮抑素治疗有可能提高放化疗疗效。
Objective To investigate the effects and mechanism of endostatin on inhibiting proliferation,cell cycle and HIF-1α protein expression in Breast carcinoma cell line MCF-7.Methods Aninhibitive proliferation effect of endostatin on MCF-7 was tested by MTT assay,the cell cycle was detected by flow cytometry(FCM),and the expression of HIF-1α by enzyme linked immunosorbent assay(ELISA).Results Endostatin could inhibit human breast carcinoma cell lines MCF-7,the inhibitory rate at 24,48,72 h was 6.9%,10.3%,43.1%,respectively,Endostatin induced a G2/M cell cycle arrest,and it also inhibited the HIF-1α protein expression with the time extending.Conclusion Endostatin can induce G2/M cell cycle arrest,which provides the basis for the inhibition of MCF-7 cell proliferation.HIF-1α is an important factor in resistance of chemotherapy and radiotherapy.Endostatin can inhibit the HIF-1α protein expression in tumor cells,so combination treatment with endostatin may improve the curative effects of radiotherapy and chemotherapy.
出处
《青海医学院学报》
CAS
2011年第2期117-120,共4页
Journal of Qinghai Medical College
基金
青海大学附属医院中青年课题基金资助(ASRF-2010-07)